SYNTHESIS OF NEW PIPERAZINYL INDOLYL PROPANONES AND PRELIMINARY CNS PHARMACOLOGICAL EVALUATION IN MICE

A.R. Subramanian, S.A.V. Raghavan, R.J. Babu, C.N.V.H.B. Gupta, N. Sridhar,
A. Veeranjanyulu, THE LATE P. Parimoo and P. Srinivas*

Department of Pharmacy, Birla Institute of Technology & Science, Pilani-333 031, India

Abstract. In a continuing programme to discover antipsychotic agents with a reduced propensity toward extrapyramidal side effects, the synthesis of a series of novel piperazinyl indolyl propanones by a mannich reaction is described. These compounds were evaluated for their dopaminergic (D_1/D_2) and serotonergic ($5-HT_2$) receptor antagonism in a preliminary in vivo pharmacological evaluation in mice and have shown antagonism to the dopaminergic (D_1/D_2) receptor, but failed to antagonize the serotonergic ($5-HT_2$) receptor to a significant extent.

Introduction

Appropriately substituted indoles have been of interest to the medicinal chemist especially because of the widespread occurrence of the indole nucleus among both naturally occurring and synthetic psychoactive compounds (1). As a result of the large number of indole derivatives that are psychoactive, it was of interest to investigate the effect of bringing in suitable pharmacophores onto an indolyl system for effective CNS function.

Numerous workers have implicated indolylalkylamines as having an important role in CNS function (2). The various structural features of indolylalkylamines which are to be considered in order to bring about structural modifications for effective CNS function are (a) the terminal amine function, (b) side-chain, and (c) the indole-1 position (3).

Of these, the terminal amine group of an indolylalkylamine interacts electrostatically with various receptors and the steric bulk of the amine plays an important role in determining the affinity. Maintaining the length of the side-chain within four methylene groups and the presence of an alkyl or an aryl/substituted aryl moiety at the indole-1 position have been reported to show varying affinities, depending on the presence of other substituents on the parent indole system (4).

In the present work, we have chosen arylpiperazines, owing to their steric bulk, as the terminal amine function, a 4-fluorophenyl moiety as the indole-1 substituent and maintaining a chain length of three methylene units between the indole system and the terminal amine function. The chemical starting point chosen for this effort was 3-acetyl indole, which is reported to be a structural template for certain CNS activities (5).

Using 3-acetyl indole as the substrate we have recently reported the first synthesis of 1-(4-fluorophenyl)-3-acetyl indole **1** by an *analogous Ullmann condensation* procedure involving 3-acetyl indole and 4-fluoroiodobenzene in the presence of a suitable catalyst (6). The active methylene of **1** would be available for further modifications by bringing in suitable pharmacophores to generate potential agents for prospective CNS activities. The Mannich reaction which is a classic three-component system in which "hydrogen active" substrates react with putative imine species that arise from condensation of an amine with an aldehyde (7), offers the best solution of bringing in a terminal amine function and a methylene onto **1**.

In this communication we report the synthesis and preliminary pharmacological evaluation of arylpiperazinyl mannich bases of 1-(4-fluorophenyl)-3-acetyl indole as Novel Piperazinyl Indolyl Propanones for prospective CNS activities.

Experimental

All melting points were determined on a Buchi model 530 melting point apparatus and are uncorrected. Infrared spectra were recorded on JASCO IR Report-100 spectrophotometer and are given in cm^{-1} recorded as a mull, unless specified. The ^1H NMR spectra, were recorded using Bruker AC 300F NMR spectrometer or Jeol GSX 400 NMR spectrometer and are reported in δ units (ppm) relative to tetramethylsilane as internal standard. Elemental analyses are indicated by the symbols of the elements and were within $\pm 0.4\%$ of the theoretical values.

General Procedure for the synthesis of Arylpiperazinyl Mannich Bases of 1-(4-fluorophenyl)-3-acetyl indole

Literature procedure (10) was used as the basis for the synthesis of products **2 a-j**. In a 50 ml round bottom flask equipped with a reflux condenser and N_2 inlet were placed 0.0024 mol of 1-(4-fluorophenyl)-3-acetyl indole **1**, 0.0036 mol of paraformaldehyde, 0.0024 mol of the N-4 unsubstituted arylpiperazine and 15 ml of absolute ethanol. The pH was adjusted to 4 and the mixture was refluxed for 29 hours. The solvent was removed under reduced pressure to give the product as the hydrochloride salt of the mannich base. Compounds whose salts were unstable were converted into their fumarates or isolated as their free bases.

1-[1-(4-Fluorophenyl)-1H-3-indolyl]-3-(4-phenyl piperazin-1-yl)-1-propanone 2a

mp. 178°C; Yield 52% (isopropyl alcohol); IR (cm⁻¹): 1640 (C=O); 1595 (aromatic); 1575 (carboxylate); 1160 (C-N). ¹H NMR (DMSO-d₆): 7.28-6.46 (m, 14H, Ar-H); 3.76-3.12 (m, 10H, CH₂); 2.51 (s, 2H, CH₂). Anal. C₂₇H₂₆N₃OF.C₄H₄O₄

3-[4-(3-Chlorophenyl)piperazin-1-yl]-1-[1-(4-fluorophenyl)-1H-3-indolyl]-1-propanone 2b

mp 145°C; Yield 47% (methanol-ether); IR (cm⁻¹): 2495 (+NHCl); 1640(C=O); 1595 (aromatic); 1550, 1180 (C-N). ¹H NMR (DMSO-d₆): 8.30-6.73 (m, 13H, Ar-H); 3.76-2.84 (m, 10H, CH₂); 2.57 (s, 2H, CH₂). Anal. C₂₇H₂₅N₃OFCl. 2HCl

3-[4-(4-Chlorophenyl)piperazin-1-yl]-1-[1-(4-fluorophenyl)-1H-3-indolyl]-1-propanone 2c

mp 210°C; Yield 51% (methanol-ether); IR (cm⁻¹): 2495 (+NHCl); 1640(C=O); 1595 (aromatic); 1540, 1180 (C-N). ¹H NMR (DMSO-d₆): 8.29-6.57 (m, 13H, Ar-H); 3.99-2.90 (m, 10H, CH₂); 2.60 (s, 2H, CH₂). Anal. C₂₇H₂₅N₃OFCl. 2HCl.

1-[1-(4-Fluorophenyl)-1H-3-indolyl]-3-(4-(4-fluorophenyl)piperazin-1-yl)-1-propanone 2d

mp 175°C; Yield 49% (methanol-ether); IR (cm⁻¹): 2475 (+NHCl); 1640(C=O); 1605 (aromatic); 1520, 1180 (C-N). ¹H NMR (DMSO-d₆): 8.32-7.05 (m, 13H, Ar-H); 3.77-3.16 (m, 10H, CH₂); 2.52 (s, 2H, CH₂). Anal. C₂₇H₂₅N₃OF. 2HCl

1-[1-(4-Fluorophenyl)-1H-3-indolyl]-3-[4-(2-methoxyphenyl)piperazin-1-yl]-1-propanone 2e

mp 135°C; Yield 46% (methanol-ether); IR (cm⁻¹): 2475 (+NHCl); 1650(C=O); 1595 (aromatic); 1530, 1180 (C-N); 1235 (Ar-O-CH₃). ¹H NMR (DMSO-d₆): 8.32-6.93 (m, 13H, Ar-H); 3.80-3.31 (m, 10H, CH₂); 3.20 (s, 3H, Ar-O-CH₃); 2.52 (s, 2H, CH₂). Anal. C₂₈H₂₈N₃O₂F. 2HCl

1-[1-(4-Fluorophenyl)-1H-3-indolyl]-3-[4-(3-methoxyphenyl)piperazin-1-yl]-1-propanone 2f

mp 90°C; Yield 49% (ethanol-petroleum ether); IR (cm⁻¹): 1660(C=O); 1600 (aromatic); 1520, 1180 (C-N); 1260 (Ar-O-CH₃). ¹H NMR (DMSO-d₆): 8.47-6.38 (m, 13H, Ar-H); 3.99-3.49 (m, 10H, CH₂); 3.07 (s, 3H, Ar-O-CH₃); 2.58 (s, 2H, CH₂). Anal. C₂₈H₂₈N₃O₂F

1-[1-(4-Fluorophenyl)-1H-3-indolyl]-3-[4-(4-methoxyphenyl)piperazin-1-yl]-1-propanone 2g

mp 151°C; Yield 54% (methanol-ether); IR (cm⁻¹): 2350 (+NHCl); 1645(C=O); 1600 (aromatic); 1510, 1180 (C-N); 1210 (Ar-O-CH₃). ¹H NMR (DMSO-d₆): 8.31-6.83 (m, 13H, Ar-H); 3.69-3.36 (m, 10H, CH₂); 3.22 (s, 3H, Ar-O-CH₃); 2.52 (s, 2H, CH₂). Anal. C₂₈H₂₈N₃O₂F. 2HCl

1-[1-(4-Fluorophenyl)-1H-3-indolyl]-3-[4-(3-trifluoromethyl phenyl) piperazin-1-yl]-1-propanone 2h

mp 220°C; Yield 59% (methanol-ether); IR (cm⁻¹): 2525 (+NHCl); 1650(C=O); 1590 (aromatic); 1540, 1175 (C-N); 1120 (CF₃). ¹H NMR (DMSO-d₆): 8.33-7.10 (m, 13H, Ar-H); 3.99-3.03 (m, 10H, CH₂); 2.51 (s, 2H, CH₂). Anal. C₂₈H₂₅N₃OF₄. 2HCl

1-[1-(4-Fluorophenyl)-1H-3-indolyl]-3-[4-(2-pyridyl)piperazin-1-yl]-1-propanone 2i

mp 265°C; Yield 62% (methanol-ether); IR (cm⁻¹): 2475 (+NHCl); 1640(C=O); 1590 (aromatic); 1530, 1180 (C-N); 1545(C=N). ¹H NMR (DMSO-d₆): 8.27-6.99 (m, 13H, Ar-H); 3.93-3.27 (m, 10H, CH₂); 2.53 (s, 2H, CH₂). Anal. C₂₆H₂₅N₄OF. 2HCl

1-[1-(4-Fluorophenyl)-1H-3-indolyl]-3-[4-(2-pyrimidinyl)piperazin-1-yl]-1-propanone 2j

mp 235°C; Yield 61% (methanol-ether); IR (cm⁻¹): 2510 (+NHCl); 1630(C=O); 1590 (aromatic); 1530, 1180 (C-N); 1565 (C=N). ¹H NMR (DMSO-d₆): 8.47-6.73 (m, 12H, Ar-H); 4.00-3.15 (m, 10H, CH₂); 2.65 (s, 2H, CH₂). Anal. C₂₅H₂₄N₅OF. 2HCl

Pharmacology

Literature reports suggest that the orientation of therapeutic activity for indoles substituted with a 4-fluorophenyl moiety at the indolyl nitrogen, predominantly are towards treatment of various psychotic disorders (11) depending on other substituents present on the molecule. The main receptors targeted for such types of activities are the dopamine (D_1/D_2) and serotonin (5-HT₂) receptors.

Evaluation of Apomorphine-induced Cage Climbing Behaviour

Male albino mice were used. The effect of pretreatment with 30 mg/kg doses of the test compounds on apomorphine (0.5 mg/kg)-induced cage climbing behaviour was studied by a literature method (12). Haloperidol, 1.0 mg/kg (i.p.) was used as control as it completely inhibited the climbing induced by apomorphine.

Evaluation of Reversal of Haloperidol-induced Catalepsy [HIC]

Male albino mice were tested for catalepsy by a literature method (13). Catalepsy was scored by a literature method (14). The test compounds (30 mg/kg) were injected 30 minutes before the injection of haloperidol (0.25 mg/kg). The catalepsy score was recorded at 30, 60, 120 and 180 minutes after haloperidol administration. The percentage reversal is calculated as a percentage of the difference between the total points obtained between control and test drugs.

Results & Discussion

Ten novel arylpiperaziny l mannich bases of 1-(4-fluorophenyl)-3-acetyl indole have been synthesized. Mannich reaction of 1-(4-fluorophenyl)-3-acetyl indole with various arylpiperazines using paraformaldehyde in ethanol gave the arylpiperaziny l mannich bases in 46-62% yields. The lower yields are attributed to the large bulk of the N-4 unsubstituted arylpiperazines, which were used as the secondary amines for the mannich reaction in this study.

The target compounds were screened for dopaminergic (D_1/D_2) receptor for antagonism of apomorphine induced climbing in mice in vivo. This screening method is predictive of potential antipsychotic activity since all clinically effective neuroleptics antagonize climbing and possess dopamine (D_1/D_2) antagonist properties (15).

Of the compounds evaluated for their antagonism to dopamine (D_1/D_2) receptors in the inhibition of apomorphine induced climbing behaviour in mice, compounds **2h**, **2h** & **2i** have shown higher antagonism, whereas compounds **2a**, **2c**, **2f** & **2i** on the other hand have shown lower antagonism (Table 1). All clinically effective antipsychotic agents act as antagonists at the dopaminergic (D_1/D_2) receptor (16) whose blockade is also associated with extrapyramidal side-effects (EPS).

Induction of catalepsy is viewed as a compounds ability to cause EPS in man and antagonism of the serotonergic (5-HT₂) receptor has been reported to block or reverse the HIC (17,18).

These compounds were further evaluated for their *atypicality* in antipsychotic activity by their ability to reverse the catalepsy induced by haloperidol. Of these, only compounds **2a**, **2b**, **2h** & **2i** showed minimal reversal of HIC indicating a probable lack of antagonism at serotonin (5-HT₂) receptors. (Table 1)

Table 1. Results of 1-(4-fluorophenyl)- piperazinyl indolyl propanones [2a-j] for their inhibition of apomorphine induced climbing behaviour (A) and reversal of haloperidol induced catalepsy in mice (B).

Compound No.	R	A	B
2a	Phenyl	36.4 ± 6.3	14.41 ± 4.6
2b	3-Chlorophenyl	58.3 ± 5.9	18.75 ± 6.3
2c	4-Chlorophenyl	25.4 ± 6.3	≠
2d	4-Fluorophenyl	≠	#
2e	2-Methoxyphenyl	≠	#
2f	3-Methoxyphenyl	24.6 ± 7.9	≠
2g	4-Methoxyphenyl	≠	#
2h	3-Trifluoromethyl phenyl	69.5 ± 8.5	20.83 ± 5.8
2i	2-Pyridyl	72.6 ± 5.3	33.33 ± 5.7
2j	2-Pyrimidinyl	25.6 ± 6.4	≠
Haloperidol	-	100	Nil

≠ - Not Significant. Inhibition less than 10%; # - Not Tested

A - % Inhibition of apomorphine induced climbing (Mean ± S.E.)

B - % Reversal of haloperidol induced catalepsy (Mean ± S.E.)

The D₁/D₂ antagonism exhibited provides a strong point towards the antipsychotic behaviour of these compounds.

Our approach was based on the scope offered by indolylalkylamines for structural modification towards effective CNS function. Although the amine moieties used were arylpiperazines, which are the basic structural templates with affinities for the 5-HT receptors, we observed that the compounds failed to antagonize 5-HT₂ receptors. Though a 4-fluorophenyl moiety on an indolyl system has been reported (11) for high affinity at the 5-HT₂ receptor, it should be noted that the presence of other pendant substituents on the indolyl system determines the specificity for a particular receptor subtype.

In another study, the replacement of the 4-fluorophenyl moiety with a 4-fluorobenzoyl moiety on the same indolyl system has been found to enhance the 5-HT₂ antagonism along with the required dopamine antagonism providing good lead molecules for *atypicality* in antipsychotic activity (unpublished results).

In view of the involvement of D₁/D₂ receptor antagonism (in inhibition of apomorphine-induced climbing behaviour) and possible role of 5-HT₂ antagonism (in haloperidol-induced catalepsy reversal), the present study needs further investigations to specify the structural features of these compounds for enhancement of their selectivity for serotonergic and dopaminergic receptors and their subtypes for their modulatory action.

Acknowledgement

The financial assistance provided by the University Grants Commission, New Delhi is thankfully acknowledged.

References & Notes

1. A. Mahamadi, P. Parimoo, W.G. Haney, B.F. Grabowski. *J. Pharm. Sci.*, **62**, (3) 490-492 (1973)
2. V. Erspamer, in "Progress in Drug Research", vol.3, E.Jucker, Ed., Interscience Publishers, Inc., New York, N.Y. (1961) p161, 329.
3. R.A. Glennon, P.K. Gessner. *J. Med. Chem.*, **22**, (4) 428-432 (1979)
4. J. Offermeier, E.J. Ariens. *Arch. Int. Pharmacodyn. Ther.*, **164**, 216 (1966)
5. H.H. Keasling, R.E. Willette, J. Szmuszkovicz. *J. Med. Chem.*, **7**, 94-96 (1964)
6. A.R.Subramanian, S.A.V.Raghavan, R. Jagadeesh Babu, C.N.V.H.B.Gupta, A.Veeranjaneyulu, P.Parimoo, P. Srinivas. *Heterocyclic Communications* (in press)
7. M. Tramontini, L.Angiolini. in "Mannich Bases: Chemistry and Uses," CRC Press Inc, Boca Raton, FL 1994
8. J.E. Saxton. *J. Chem. Soc.*, (P) 3592 (1952)
9. Data for 3-acetyl indole : prepared from indole using acetic anhydride and glacial acetic acid (9:1) to give 1,3-diacetylindole in overall 62% yield, followed by hydrolysis with aqueous 2N NaOH to give 3-acetyl indole in 76% yield as long colorless prisms, m.p.191°C. IR (cm⁻¹) [KBr]: 3400(N-H); 1650(C=O); 1605 (aromatic); 745(1,2-disubstitutedbenzene). ¹HNMR(DMSO-d₆): δ 7.99-6.81 (m, 6H, Ar-H); δ 2.20 (s, 3H, CH₃). Anal. C₁₀H₉NO
10. J. Szmuszkovicz. *J. Am. Chem. Soc.*, **82**, 1180-1186 (1960)
11. J. Perregaard, J. Arnt, P.B. Klaus, J. Hyttel, C. Sanchez, C. J. Med. Chem., **35**, 1092 (1992). J. Perregaard, K. Andersen, J. Hyttel, C. Sanchez. *J. Med. Chem.*, **35**, 4813 (1992). J. Perregaard, J. Arnt, K. Andersen, J.B. Nielsen, M. Begtrup. *J. Med. Chem.*, **35**, 4823 (1992).
12. G. Costall, R.J. Naylor, V. Nohria. *Eur. J. Pharmacol.*, **50**, 39-50 (1978)
13. B. Costall, R.J. Naylor. *Eur. J. Pharmacol.*, **27**, 46-58 (1974b)
14. P.A. Shore, R.L. Dorris. *Eur. J. Pharmacol.*, **30**, 315-318 (1975)
15. N.J.Hrib, J.G.Jurcak, F.P.Huger, C.L.Errico, R.W.Dunn. *J. Med. Chem.*, **34**, 1068-1072 (1991)
16. I. Casariego, C.F. Masaguer, E. Ravina. *Tetrahedron Letters*. **38**, (31) 5555-5558 (1997)
17. P.B. Hicks. *Life Sci.*, **47**, (18) 1609-1615 (1990)
18. S. Kapur. *Psychopharmacology*. **124**, 35-39 (1996)

Received on November 7, 1998